Versameb – the next generation of RNA therapeutics

RNA therapeutics are a new class of medicines that have a broad applicability targeting disease relevant proteins. Proteins are large and complex molecules that play a critical role in the body’s capacity to be healthy. Currently, most approved drugs are small molecules and protein biologics, which can only target a very limited number of proteins or genes. Our RNA-based therapeutics can be used to selectively trigger protein overexpression or downregulation, for single or multiple protein targets with one RNA construct. This uncovers new therapeutic possibilities for previously undruggable targets.

The VERSagile platform

The platform is amenable to any nucleotide therapy. There are currently 2 different pillars within our platform that can be used synergistically or independently to create the best therapeutic.

Protein Secretion Pillar

Our cells use messenger RNA (mRNA) to translate DNA (genes) into proteins which are required for the healthy function of the human body. Expression of disease-relevant proteins can be achieved by molecular targeting of a specific gene through mRNA. Versameb’s technology aims to use mRNA to direct a patient’s cells to manufacture their own functional proteins and help the body heal itself to protect against disease.

Versameb has discovered and developed ways to optimize protein production and secretion through employing modifications in mRNA coding information, thereby controlling the translation and processing of disease related proteins. Its VERSagile technology platform offers the potential to produce several new molecular entities that show different tissue specificity for one therapeutic target. This ensures the full exploration of its therapeutic value in different tissues and hence disease areas.

Versameb’s proprietary modifications of mRNA molecules translate into tailor-made protein expression and targeting by safely shuttling the therapy out of the cell. This optimization increases the therapeutic window and allows access to different disease targets and various cell types which were not amenable by common mRNA approaches.

Currently, we have proof of concept (PoC) in different tissues and for different protein classes including growth factors, hormones and cytokines. A significant increase in protein production and secretion as well as accelerated functional regeneration has been proven in various preclinical studies across multiple therapeutic applications. Our platform works as an innovation engine allowing us to rapidly generate new molecules for different targets and tissues.

The team is initially focusing on areas where localized delivery is the most appropriate way to address the clinical and biological drivers of the targeted disease. Our technology is equally applicable to therapies where systemic delivery would be optimal. The company is rapidly expanding into potential new targets and indications.

Multi-protein target pillar

The multi-protein platform focuses on RNA molecules that simultaneously target more than one therapeutic protein, thereby up- and/or down-regulating these proteins independently. With the multi-protein platform, VERSAMEB is capable of applying linked and synergistic therapeutic concepts, e.g. immunomodulatory, anti-inflammatory and pro-regenerative mechanisms, within one drug candidate.

Given the immense potential of combinatory therapeutic approaches VERSAMEB is exploring oncology to validate its multi-protein platform in cancer therapies. The team is applying the combinatory approach to target scientifically established target mechanisms associated with cancer progression, metastasis or chemoresistance in one therapeutic molecule. The biological mechanisms targeted by these molecules are expected to apply to multiple tumor types.